Make your money go further for just 25p per day

PREMIUM

Bioventix: delightful as always

30/10/2023 · Bioventix PLC (BVXP) 

Flock of sheep

This highly unusual company continues to deliver excellent results and wonderful cash flow. We are also impressed with the clear explanation provided of their somewhat complicated activities; other AIM companies should take note. Read on here to find out more about this delightful company. 


Bioventix (AIM:BVXP), which specialises in the area of antibodies for applications in clinical diagnostics, has announced excellent results for its financial year ending 30 June 2023.

This is a highly unusual AIM company, which we first covered in 2015, since when the shares have climbed over 350% and paid out substantial dividends as well. So what’s so unusual about this business?

Bioventix creates and manufactures high affinity sheep monoclonal antibodies…

Continue reading our content…

Gain access to all our excellent content for just £90 per year, that’s just 25p per day for financial freedom.
  • Unlimited access to our market-beating portfolios
  • In-depth coverage of many of the world’s great companies
  • Unique insights from our top research team
Register FREE for access to limited content.
  • Company and markets insights
  • Sponsored content
  • Podcasts

Previous article Next article

DON'T MISS OUT!

Get top investment ideas to help safeguard and grow your wealth.

Invaluable insight from the exciting world of smaller companies.

REGISTER FREE

DON'T MISS OUT ON OUR PREMIUM CONTENT

Become a champion investor for just £90 a year. Benefit from our high performing portfolios:

START FREE TRIAL

More on Bioventix PLC

Bioventix: delightful as always

30/10/2023 · Company Insights

This highly unusual company continues to deliver excellent results and wonderful cash flow. We are also impressed…


Accounting shenanigans | Dividends | Contract wins

27/03/2023 · Company Insights

Results and updates covered here include news of encouraging contract wins as well as a big…


More Company Insights

Resilience in animal healthcare

Utter gobbledygook | Tough to value

When boring is best

Sign-up to our free email updates

SIGN UP